Registry Guidance Sought Following HHS Privacy Rule Implementation
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers seeking protected health information (PHI) from covered entities for postmarket surveillance will need to take precautions to ensure their studies are subject to FDA oversight, and thereby exempted from HHS' privacy rule.